Press "Enter" to skip to content

Pfizer’s atopic dermatitis treatment meets goals in late-stage study

Abrocitinib, which belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as Janus kinases, achieved statistically significant improvement in clearing the skin of patients as compared to placebo.

Original source: